Introduction
Patients with Nasopharyngeal carcinoma (NPC) carry lower amounts of tumor-specific CD8 cells than healthy people. EBaT8 is a novel T-cell product for NPC precision cell therapy. It includes interferon-α during manufacturing process for antigen-presenting cell and T-cell response. The procedure can generate more cytotoxic effects against NPC tumor cells.
Features / strengths
Far Eastern Memorial Hospital cooperates with FullHope Biomedical to conduct a clinical trial to validate the efficacy and safety of EBaT8 in treating NPC.
Specification in detail
Brand
FullHope Biomedical
